BiomX Inc. – AMEX:PHGE-UN

BiomX stock price today

$3.5
+3.16
+929.41%
Financial Health
0
1
2
3
4
5
6
7
8
9

BiomX stock price monthly change

-19.43%
month

BiomX stock price quarterly change

-11.50%
quarter

BiomX stock price yearly change

+17.24%
year

BiomX key metrics

Market Cap
 10.76M
Enterprise value
 8.91B
P/E
 -0.23
EV/Sales
 N/A
EV/EBITDA
 372.65
Price/Sales
 N/A
Price/Book
 424.27
PEG ratio
 N/A
EPS
 -0.52
Revenue
 -354K
EBITDA
 -17.65M
Income
 -29.61M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 4987.57%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

BiomX stock price history

BiomX stock forecast

BiomX financial statements

Profit Margin

BiomX Inc. (AMEX:PHGE-UN): Profit margin
Jun 2023 -90K -6.41M 7123.33%
Sep 2023 -89K -382K 429.21%
Dec 2023 -87K -5.49M 6311.49%
Mar 2024 -88K -17.32M 19689.77%
PHGE-UN income statement history

BiomX Financials Estimate

BiomX Inc. (AMEX:PHGE-UN): Analyst Estimates
Dec 2023 -87K -5.49M 6311.49%
Mar 2024 -88K -17.32M 19689.77%
Oct 2025 -122.98K -3.11M 2532.56%
Dec 2025 -130.03K -3.73M 2874.17%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

BiomX Inc. (AMEX:PHGE-UN): Debt to assets
Jun 2023 41253000 25.38M 61.54%
Sep 2023 33056000 24.90M 75.33%
Dec 2023 58156000 55.07M 94.7%
Mar 2024 81606000 58.73M 71.97%
PHGE-UN balance sheet history

Cash Flow

BiomX Inc. (AMEX:PHGE-UN): Cash Flow
Jun 2023 -4.07M -1K 4.48M
Sep 2023 -5.92M -32K -1.30M
Dec 2023 -6.24M -6K -1.32M
Mar 2024 -11.35M 663K 38.97M
PHGE-UN cash flow history

BiomX alternative data

BiomX
Employees

BiomX Inc. (AMEX:PHGE-UN): Employee count
Aug 2023 54
Sep 2023 54
Oct 2023 54
Nov 2023 54
Dec 2023 54
Jan 2024 54
Feb 2024 54
Mar 2024 54
Apr 2024 54
May 2024 54
Jun 2024 58
Jul 2024 58

BiomX other data

BiomX
Insider Trading

BiomX Inc. (AMEX:PHGE-UN): Insider trades (number of shares)
Period Buy Sel
Nov 2019 56629 0
Dec 2019 46000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP director, 10 percent owner
 Common Stock, $0.001 par value 3,500 N/A N/A
Purchase
CHIMOVITS EREZ director, 10 percent owner
 Common Stock, $0.001 par value 3,500 N/A N/A
Purchase
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP director, 10 percent owner
 Common Stock, $0.001 par value 500 N/A N/A
Purchase
CHIMOVITS EREZ director, 10 percent owner
 Common Stock, $0.001 par value 500 N/A N/A
Purchase
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP director, 10 percent owner
 Common Stock, $0.001 par value 5,400 N/A N/A
Purchase
CHIMOVITS EREZ director, 10 percent owner
 Common Stock, $0.001 par value 5,400 N/A N/A
Purchase
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP director, 10 percent owner
 Common Stock, $0.001 par value 3,400 N/A N/A
Purchase
CHIMOVITS EREZ director, 10 percent owner
 Common Stock, $0.001 par value 3,400 N/A N/A
Purchase
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP director, 10 percent owner
 Common Stock, $0.001 par value 6,000 N/A N/A
Purchase
CHIMOVITS EREZ director, 10 percent owner
 Common Stock, $0.001 par value 6,000 N/A N/A
PHGE-UN insider trading transactions

BiomX
Executives

Insider Compensation
Mr. Jonathan Eitan Solomon MBA (1977) Chief Executive Officer & Director
 $564,250
Dr. Merav Bassan Ph.D. (1966) Chief Devel. Officer
 $410,870

Frequently Asked Questions (FAQ)

  • What's the price of BiomX stock today?

    One share of BiomX stock can currently be purchased for approximately $3.5.

  • When is BiomX's next earnings date?

    Unfortunately, BiomX's (PHGE-UN) next earnings date is currently unknown.

  • Does BiomX pay dividends?

    No, BiomX does not pay dividends.

  • How much money does BiomX make?

    BiomX has a market capitalization of 10.76M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 166.42% to -357K US dollars.

  • What is BiomX's stock symbol?

    BiomX Inc. is traded on the AMEX under the ticker symbol "PHGE-UN".

  • What is BiomX's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of BiomX?

    Shares of BiomX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are BiomX's key executives?

    BiomX's management team includes the following people:

    • Mr. Jonathan Eitan Solomon MBA Chief Executive Officer & Director(age: 48, pay: $564,250)
    • Dr. Merav Bassan Ph.D. Chief Devel. Officer(age: 59, pay: $410,870)

  • How many employees does BiomX have?

    As Jul 2024, BiomX employs 58 workers, which is 7% more then previous quarter.

  • When BiomX went public?

    BiomX Inc. is publicly traded company for more then 5 years since IPO on 31 Oct 2019.

  • What is BiomX's official website?

    The official website for BiomX is biomx.com.

  • How can i contact BiomX?

    BiomX can be reached via phone at +972 72 394 2377.

BiomX company profile:

BiomX Inc.

biomx.com
Exchange:

AMEX

Full time employees:

58

Industry:

Biotechnology

Sector:

Healthcare

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

+972 72 394 2377
22 Einstein Street
Ness Ziona, 7414003

CIK: 0001739174
ISIN: US09090D1037
: